SCHEMBL24310131

SCHEMBL24310131

Cc1ccccc1Oc1nc(N[S+]([O-])c2cnn(C)c2)nc(-c2ccccc2CC(C)C)c1C(F)(F)C(F)(F)F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24310453 0.86 — —
SCHEMBL29567023 0.83 HTR1A (0.35) —
SCHEMBL24310132 0.83 HTR1A (0.35) —
SCHEMBL24310154 0.80 — —
SCHEMBL24310186 0.78 CTSC (0.35) —
SCHEMBL24310776 0.77 CTSC (0.37) —
SCHEMBL24310092 0.77 MAP4K1 (0.31) —
SCHEMBL24309552 0.76 MAPK7 (0.32) —
SCHEMBL24309562 0.76 FLT4 (0.32) —
SCHEMBL24310531 0.75 CTSC (0.32) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed
Send feedback